AI/Nov 14 edition/Reporting & analysis
ModelsResearch

ModelsArchitectures & capability

Google DeepMind's AlphaGenome 2 predicts DNA variant effects for specific cell types and cell states

Google DeepMind's AlphaGenome 2 makes its DNA-variant predictions for a specific tissue, cell type or cell state. Researchers can see which cells a variant acts in. The original model gave tissue-wide averages, which can hide those effects.

From the r/AISEOInsider (via last30days) article of November 13, 2026 and cited sources: AlphaGenome 2 reads about one million DNA letters plus one chosen biological condition at a time. [2] [8] [3]

SOURCES[2] AlphaGenome 2: Deciphering how cells read DNA… deepmind.google[8] Google DeepMind's AlphaGenome 2 Predicts Cell-State… unite.ai[3] AlphaGenome 2 Predicts DNA Variant Effects by Cell Type… implicator.ai

AI-assisted, not human-edited. Methodology Corrections Who owns this site

KEY FACTS
What happened
AlphaGenome 2 reads about one million DNA letters plus one chosen biological condition at a time. [2] [8] [3]
Original source
r/AISEOInsider (via last30days) article, independent perspective
Brief by
AT Pulse research desk AI-assisted; publisher and contact on the desk page
When
November 13, 2026 article published
Evidence
11 sources across 9 sites

Reach: not measured yet

THE CORE IDEAS3 TAKEAWAYS
01

AlphaGenome 2 reads about one million DNA letters plus one chosen biological condition at a time. That condition shapes the whole network, not just the final output. A condition can come from a reference catalog or from a user's own single-cell RNA-seq data without fine-tuning, and about 30 cells are reportedly enough for a new state. The model was trained on more than 100 million single-cell profiles. [2] [8] [3]

02

On DeepMind's own TenK10K immune-cell benchmark, the model found 30% of likely causal expression variants at 90% precision. The original model found 16%. It also predicted the direction of effect correctly more often: 43% versus 23%. These gains are real, but most likely causal variants are still missed. [2] [8]

03

The model predicts gene expression, splicing, chromatin accessibility, histone marks and, new in this version, CpG DNA methylation. It is free through the AlphaGenome API for non-commercial research. Commercial research access is limited to a private preview. The model is not approved for clinical or diagnostic use. [2] [8]

WHY IT MATTERS

The evidence shows better recall on one immune-cell benchmark, not clinical validity. If the gains hold, genetics and drug-discovery teams could narrow which cell types to test experimentally when picking targets.

Read the full assessment

Locally calibrated scores and lab confirmation would still be needed.

Executive brief

Google DeepMind's AlphaGenome 2, announced 11 November 2026, predicts how a DNA change affects gene regulation in a particular cell type or state. Its predecessor could only give tissue-wide averages. On DeepMind's TenK10K immune-cell benchmark, it recovered 30% of causal expression variants at 90% precision. The original model recovered 16% (DeepMind). That is still a minority of likely causal variants. The benchmark comes from an unpublished preprint, and no independent test of version 2 has been reported (Implicator). The Reddit post that prompted this dossier is commentary and adds no evidence of its own.

What changed and event timeline

  1. AlphaGenome debuts

    DeepMind released a model that reads 1 Mb of DNA and predicts thousands of regulatory signals, such as gene activity and splicing, for variant-effect research ().

  2. Peer-reviewed in Nature

    The paper reports that AlphaGenome matches or beats the strongest external models in 25 of 26 variant-effect evaluations. Wellcome Sanger Institute tests found strong but imperfect performance (;).

  3. Calibration critique

    A Charité-affiliated preprint argues that AlphaGenome's scores are not on a common physical scale across genome locations, so they need local calibration before being compared. It also reports over-dispersion at promoters ().

  4. Promoter-effect shortfall

    A Charité-led preprint reportedly found that the original model often failed to carry promoter-disruption effects through to the predicted transcripts ().

  5. AlphaGenome 2 launches

    The new model conditions its predictions on a tissue, cell type or cell state. It was trained on more than 100 million single-cell profiles and is free for non-commercial research (;).

Capabilities and access

  • Model: AlphaGenome 2 takes a 1-million-letter DNA sequence plus one biological condition at a time (DeepMind).
  • Outputs: gene expression, RNA splicing, chromatin accessibility, histone modifications and CpG DNA methylation. Methylation is new in this version (Unite.AI).
  • Access: free through the AlphaGenome API for non-commercial research, with a private preview for commercial research.
Read the full section
  • Model: AlphaGenome 2 takes a 1-million-letter DNA sequence plus one biological condition at a time (DeepMind).
  • Outputs: gene expression, RNA splicing, chromatin accessibility, histone modifications and CpG DNA methylation. Methylation is new in this version (Unite.AI).
  • Access: free through the AlphaGenome API for non-commercial research, with a private preview for commercial research. DeepMind says "AlphaGenome 2 Skills" are coming to Google Antigravity (DeepMind).
  • Use restriction: research only. The model is not validated or approved for clinical use.

Technical analysis for researchers and developers

  • Conditioning: the chosen cell context is fed through the whole network, not added at the output (Unite.AI).
  • Cell encoder: the condition can come from a reference catalog or be built from a user's own single-cell RNA-seq data, with no fine-tuning.
  • Cross-modality imputation: DeepMind says the model can predict properties that were not measured from a single measured readout (DeepMind).
Read the full section
  • Conditioning: the chosen cell context is fed through the whole network, not added at the output (Unite.AI).
  • Cell encoder: the condition can come from a reference catalog or be built from a user's own single-cell RNA-seq data, with no fine-tuning. Reportedly about 30 cells are enough for a new state (Implicator).
  • Cross-modality imputation: DeepMind says the model can predict properties that were not measured from a single measured readout (DeepMind).
  • Training data: DeepMind cites over 107 million cell profiles from 68 tissues, while press coverage rounds this to "100M+".
  • Evaluation: TenK10K, 28 immune cell types, scored as recall at fixed precision. The fixed-precision setup is what matters for prioritising variants.
  • Reproducibility: the benchmark is in a preprint. The original model's weights were posted on Hugging Face; weights for version 2 are not reported.

Claims and evidence

All of the following come from DeepMind and have not been checked independently:

Read the full section

All of the following come from DeepMind and have not been checked independently:

  • Causal variants: 30% recovered at 90% precision, versus 16% for the original model (Unite.AI).
  • Direction of effect (whether a variant raises or lowers gene activity): 43% correct at 90% accuracy, versus 23%.
  • Variance explained: a median of 34% of cell-type-specific expression variance, versus 23%.
  • Anecdote: Crick Institute immunologist James Lee said the model reproduced 18 months of his lab's work on ETS2 in gut macrophages (an inflammatory bowel disease finding) in about 30 minutes (Implicator). This is a single case reported through DeepMind's launch materials, not a systematic test.

Context and prior work

  • Original AlphaGenome: its Nature results (22 of 24 genome-track tasks, 25 of 26 variant-effect tasks) and the Sanger testing apply to version 1, not version 2 (Science Media Centre Spain).
  • What version 2 targets: tissue-level models dilute variants that act only in rare or disease-activated cells (Unite.AI).
  • Partners named: Wellcome Sanger Institute, Human Cell Atlas and Genomics Ltd (DeepMind).
Read the full section
  • Original AlphaGenome: its Nature results (22 of 24 genome-track tasks, 25 of 26 variant-effect tasks) and the Sanger testing apply to version 1, not version 2 (Science Media Centre Spain).
  • What version 2 targets: tissue-level models dilute variants that act only in rare or disease-activated cells (Unite.AI).
  • Partners named: Wellcome Sanger Institute, Human Cell Atlas and Genomics Ltd (DeepMind).

Limitations, safety and contested findings

  • DeepMind's own caveats: the model still recovers only a minority of likely causal and disease variants.
  • Critiques of version 1: independent preprints challenge its promoter handling and whether scores can be compared across genome locations (Preprints.org; Implicator).
  • Clinical use: not approved for clinical or diagnostic use.
Read the full section
  • DeepMind's own caveats: the model still recovers only a minority of likely causal and disease variants. It underestimates distant regulatory elements, and transient or disease cell states are underrepresented in training. Its cell-state representations reflect correlation, not causation, and it is unclear whether it can predict gene knockouts or cell-state transitions (Unite.AI).
  • Critiques of version 1: independent preprints challenge its promoter handling and whether scores can be compared across genome locations (Preprints.org; Implicator). The reviewed sources do not show whether version 2 fixes these problems.
  • Clinical use: not approved for clinical or diagnostic use.

Business and practitioner implications

  • Who benefits: genetics teams screening variants found by association studies can now ask which cell type a variant acts in.
  • Before relying on scores: calibrate them locally, especially near promoters, and confirm key predictions experimentally.
  • Commercial access: commercial users are limited to the private preview.
Read the full section
  • Who benefits: genetics teams screening variants found by association studies can now ask which cell type a variant acts in. That could help pick drug targets and choose which experiments to run.
  • Before relying on scores: calibrate them locally, especially near promoters, and confirm key predictions experimentally.
  • Commercial access: commercial users are limited to the private preview.
  • Industry sentiment: Benzinga framed the launch against drugmakers' skepticism about AI (Benzinga).
FOLLOW THE EVIDENCE

The source trail.

Sources (11)
A LITTLE LESS NOISE. A LOT MORE CONTEXT.

Stay curious.
Follow the evidence.

Independent perspectives, the original sources, and room for the questions that don't have easy answers.

How we build the brief
Connect with us

Find us where you already read.